KROS Stock Analysis: Buy, Sell, or Hold?
KROS - Keros Therapeutics, Inc. Common Stock
$10.67
0.06 (0.57%)
▲
5d:
-5.07%
30d:
-24.81%
90d:
-49.26%
HOLD
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 05, 2026
Smart Money Accumulation
KROS is down 17.6% this week, but smart money is accumulating calls. Top strike: $12.5 2026-04-17 with 1 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When KROS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: KROS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: KROS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: KROS is currently trading at $10.67, which is considered slightly low relative to its 30-day fair value range of $10.56 to $14.44.
Technical Outlook: Technically, KROS is in a strong downtrend. The price is currently testing key support at $10.41. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KROS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $22.57 (+112.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, KROS is in a strong downtrend. The price is currently testing key support at $10.41. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KROS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $22.57 (+112.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$10.56 -
$14.44
Company Quality Score
61/100
(BUY)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
75.0%
Protect Your Profits
Holding KROS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 100th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 112.7% below Wall St target ($22.57)
- CAUTION: Recommendation downgraded due to -5.1% 5-day decline
Fair Price Analysis
30-Day Fair Range
$10.56 -
$14.44
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$2.77
(26.0%)
Support & Resistance Levels
Support Level
$10.42
Resistance Level
$11.60
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.10
Wall Street Target
$22.57
(+112.7%)
Revenue Growth (YoY)
-87.3%
Profit Margin
35.6%
Share & Embed Analysis
Last updated: March 30, 2026 2:55 PM ET
Data refreshes hourly during market hours. Next update: 3:55 PM
Data refreshes hourly during market hours. Next update: 3:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KROS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Adar1 Capital Management…
SELL
5389264 shares
2025-10-15
Pontifax Management 4 G.…
SELL
4787331 shares
2025-10-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 56 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 63 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 45 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 54 HOLD |
Advanced KROS Option Strategies
Professional options setups generated by AI based on today's KROS price and gamma walls.
